CEFOXITIN Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Cefoxitin, and when can generic versions of Cefoxitin launch?
Cefoxitin is a drug marketed by Acs Dobfar, Acs Dobfar Spa, Fresenius Kabi Usa, Hikma, Hikma Farmaceutica, Hospira Inc, B Braun, and Samson Medcl. and is included in fourteen NDAs.
The generic ingredient in CEFOXITIN is cefoxitin sodium. There are eight drug master file entries for this compound. Six suppliers are listed for this compound. Additional details are available on the cefoxitin sodium profile page.
Summary for CEFOXITIN
US Patents: | 0 |
Applicants: | 8 |
NDAs: | 14 |
Finished Product Suppliers / Packagers: | 4 |
Raw Ingredient (Bulk) Api Vendors: | 63 |
Clinical Trials: | 17 |
Patent Applications: | 5,787 |
Formulation / Manufacturing: | see details |
Drug Prices: | Drug price information for CEFOXITIN |
DailyMed Link: | CEFOXITIN at DailyMed |
Recent Clinical Trials for CEFOXITIN
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Poitiers University Hospital | Phase 3 |
University of Calgary | Phase 2/Phase 3 |
Murdoch Childrens Research Institute | Phase 2/Phase 3 |
Pharmacology for CEFOXITIN
Drug Class | Cephalosporin Antibacterial |